Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 4

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

NCT06634797 · View on ClinicalTrials.gov ↗

Study Summary

The primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo.

Conditions Studied

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL mRNA-1273.712

Study Locations (20)

California

  • Velocity Clinical Research, Huntington Park — Huntington Park
  • Velocity Clinical Research, San Diego — La Mesa
  • Velocity Clinical Research, Banning — San Bernardino

Louisiana

  • Velocity Clinical Research, Covington — Covington
  • Velocity Clinical Research, Lafayette — Lafayette
  • Velocity Clinical Research, New Orleans — New Orleans

Nebraska

  • Velocity Clinical Research, Grand Island — Grand Island
  • Velocity Clinical Research, Lincoln — Lincoln
  • Velocity Clinical Research, Omaha — Omaha

Ohio

  • Velocity Clinical Research, Cleveland — Beachwood
  • Velocity Clinical Research, Cincinnati, Blue Ash — Blue Ash

Arizona

  • Velocity Clinical Research, Phoenix — Phoenix

District of Columbia

  • Velocity Clinical Research, Washington DC — Washington D.C.

Georgia

  • Velocity Clinical Research, Savannah — Savannah

Idaho

  • Velocity Clinical Research, Boise — Meridian

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-10-08
Est. Completion 2025-01-20
Phase Phase 4

Sponsor

ModernaTX

67 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06634797

The ClinicalTrials.gov registry entry for NCT06634797 describes a study currently listed as completed. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 67 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06634797 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, Louisiana, Nebraska. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06634797 about?

NCT06634797 is a clinical study titled "A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age". The primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo.

What is the current status of trial NCT06634797?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,000 participants. The study started on 2024-10-08. Estimated completion is 2025-01-20.

What conditions does trial NCT06634797 study?

This clinical trial studies the following conditions: Healthy Volunteers. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06634797?

The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1273.712 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06634797?

This trial is sponsored by ModernaTX, which has 67 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06634797 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial